Breast Cancer Clinical Trial
Official title:
The Effect of Tumor - Breast Volume Ratio on Cosmetic and Functional Outcomes in Breast Conserving Surgery Patients; a Prospective Cohort Study
The initial aesthetic and functional conditions are recorded with the help of the Breast
Cancer Treatment Outcome Scale (BCTOS),an international validated questionnaire, and the
Breast Cancer Conservative Treatment - cosmetic results (BCCT.core) validated computer
software, allowing for comparison. Determination of the initial quality of life is measured
with the European Organisation of Research and Treatment of Cancer - Quality of Life
Questionnaire number C30-BR23 (EORTC QoL C30-BR23).
Patients then undergo surgical treatment according to institutional protocols. Following
conventional marking of the orientation of the specimen, it is measured by an analytical
scale.
Histological examination of the specimen will record the largest diameters, and parameters
of the lymph nodes, according to the institutional protocol.
On the 4th week following surgery, assuming that wound healing is completed, patients' data
are again recorded in BCTOS, BCCT.core and EORTC QoL C30-BR23. A third set of data are
gained after completion of adjuvant radiotherapy, on the 8th postoperative month. Magnetic
resonance imaging is performed to assess the volume of the contralateral breast.
Tumor - breast volume ratio is calculated, and matched up with cosmetic results in each
quadrant, threshold value in the quadrants, above of which it is not advisable to perform
conventional breast conserving surgery due to poor outcomes.
| Status | Completed |
| Enrollment | 300 |
| Est. completion date | January 2015 |
| Est. primary completion date | January 2015 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | N/A to 70 Years |
| Eligibility |
Inclusion Criteria: - early breast cancer - unilateral tumor - tumor size is less than 3 cm Exclusion Criteria: - age over 70 - malignant invasive tumor in the past - pregnancy - previous surgical treatment of the breast or axilla - central breast tumor sizing <3 cm - a need for mastectomy - tumor size >3 cm measured by mammography or physical examination - surgical excisions resulting in positive margins - surgical or radiotherapeutic complication |
Intervention Model: Single Group Assignment, Masking: Open Label
| Country | Name | City | State |
|---|---|---|---|
| Hungary | National Institute of Oncology | Budapest |
| Lead Sponsor | Collaborator |
|---|---|
| National Institute of Oncology, Hungary |
Hungary,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Primary outcome is the determination of the critical tumor / breast volume ratio in each quadrant, above of which number breast conserving surgery could not offer adequate cosmetic and functional results. | Data of eligible patients are recorded by the study physicians on a locally developed questionnaire. Digital photos are taken of each patient producing a frontal and two side views. Images are processed by the BCCT.core software (Breast Cancer Conservation Treatment. cosmetic results). Magnetic resonance imaging is implemented and used to calculate breast volume with the help of Amira 5.1 software (Visage Imaging GmbH)trial version. Excised tumor is measured by a validated analytical scale. |
8 months | No |
| Secondary | Assessing the clinical applicability of the Breast Cancer Treatment Outcome Scale (BCTOS). | Initial cosmetic and functional status is recorded by using the validated BCTOS and the BCCT.core software. Patients then undergo surgical procedure according to institutional protocols. On the 4th postoperative week, patients status is recorded by BCTOS, BCTOS.core, EORTC QoL C30-BR23. After adjuvant radiotherapy (according to institutional protocols), in the 8th postoperative month, cosmetic and functional status and quality of life are assessed again with the same methods, and MR images are taken. |
8 months for each patient | No |
| Secondary | Assessing the relationship between cosmetic+functional results and quality of life. | Initial cosmetic and functional status is recorded by using the validated BCTOS and the BCCT.core software. Initial quality of life is assessed by the validated EORTC QoL C30-BR23. Patients then undergo surgical procedure according to institutional protocols. On the 4th postoperative week, patients status is recorded by BCTOS, BCTOS.core, EORTC QoL C30-BR23. After adjuvant radiotherapy (according to institutional protocols), in the 8th postoperative month, cosmetic and functional status and quality of life are assessed again with the same methods, and MR images are taken. |
8 months for each patient | No |
| Secondary | Assessing the effect of surgical intervention on cosmetic+functional results and quality of life. | Initial cosmetic and functional status is recorded by using the validated BCTOS and the BCCT.core software. Initial quality of life is assessed by the validated EORTC QoL C30-BR23. Patients then undergo surgical procedure according to institutional protocols. On the 4th postoperative week, patients status is recorded by BCTOS, BCTOS.core, EORTC QoL C30-BR23. After adjuvant radiotherapy (according to institutional protocols), in the 8th postoperative month, cosmetic and functional status and quality of life are assessed again with the same methods, and MR images are taken. |
During 8 postoperative months | Yes |
| Secondary | Assessing the effect of radiotherapeutical intervention on cosmetic+functional results and quality of life. | Initial cosmetic and functional status is recorded by using the validated BCTOS and the BCCT.core software. Initial quality of life is assessed by the validated EORTC QoL C30-BR23. Patients then undergo surgical procedure according to institutional protocols. On the 4th postoperative week, patients status is recorded by BCTOS, BCTOS.core, EORTC QoL C30-BR23. After adjuvant radiotherapy (according to institutional protocols), in the 8th postoperative month, cosmetic and functional status and quality of life are assessed again with the same methods, and MR images are taken. |
During 8 postoperative months | Yes |
| Secondary | Assessing the clinical applicability of the European Organisation of Research and Treatment of Cancer, Quality of Life Questionnaire C30-BR23 (EORTC QoL C30-BR23) validated questionnaire. | Initial quality of life is assessed by the validated EORTC QoL C30-BR23. Patients then undergo surgical procedure according to institutional protocols. On the 4th postoperative week, patients status is recorded by BCTOS, BCTOS.core, EORTC QoL C30-BR23. After adjuvant radiotherapy (according to institutional protocols), in the 8th postoperative month, cosmetic and functional status and quality of life are assessed again with the same methods, and MR images are taken. | 8 months | No |
| Secondary | Assessing the clinical applicability of the BCCT.core software. | Initial cosmetic and functional status is recorded by using the validated BCTOS and the BCCT.core software. Patients then undergo surgical procedure according to institutional protocols. On the 4th postoperative week, patients status is recorded by BCTOS, BCTOS.core, EORTC QoL C30-BR23. After adjuvant radiotherapy (according to institutional protocols), in the 8th postoperative month, cosmetic and functional status and quality of life are assessed again with the same methods, and MR images are taken. |
8 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |